In the second-line setting, rather than single-agent chemotherapy, Pembrolizumab has been approved for tumors that express PD-L1 (30), while Nivolumab and Atezolizumab represent a standard option regardless of tumor PD-L1 expression (31–33). Here, CD274 is linked to neoplasm.